What's New in Creatine Research: August 2026

New series. Once a month I am going to walk through what actually landed in creatine research, in plain language, including the parts that do not flatter us.

That last bit matters. Most brand "research roundups" are a list of studies that agree with the product. This month's headline study genuinely complicates something we have written elsewhere on this blog, and I would rather point at it myself than hope nobody notices.

What was the biggest creatine study this year?

The CONCRET-MENOPA trial, published in the Journal of the American Nutrition Association, is the first randomized controlled trial designed specifically to test creatine supplementation in perimenopausal and menopausal women.

That framing is the news by itself. For decades, creatine research ran overwhelmingly on young men. A trial built from the ground up around women in the menopause transition is a real shift in who this science is being done for.

The design: 36 healthy perimenopausal and menopausal women, mean age about 50, randomized double-blind across four arms for eight weeks — low-dose creatine hydrochloride, medium-dose creatine hydrochloride, a creatine hydrochloride plus creatine ethyl ester combination, and placebo. It was pre-registered on ClinicalTrials.gov as NCT06660004.

What did the trial actually find?

The medium-dose creatine hydrochloride group outperformed placebo on reaction time, on frontal brain creatine levels, and on serum lipid profile, with a trend toward reduced mood swing severity.

The frontal brain creatine number is the one I find most interesting. It is direct evidence that supplementation actually moved creatine into brain tissue, not just muscle — which is the mechanism the whole brain-energy conversation depends on. We laid that mechanism out in brain bioenergetics and cognitive health.

Why does this study complicate our own advice?

Because it used creatine hydrochloride and creatine ethyl ester rather than creatine monohydrate, and at doses far below the 5g standard we normally point people to.

We have written, more than once, that monohydrate is the form with the evidence and that HCl is marketed on solubility without matching outcome research. Our forms comparison says exactly that.

This trial is a data point on the other side. The effective arm was 1,500mg a day of creatine HCl — not 5g, and not monohydrate.

Does that overturn the monohydrate position? No. One 36-person trial does not outweigh decades of monohydrate research, and it did not test monohydrate as a comparator, so it cannot tell us HCl beat monohydrate — only that it beat placebo. But it does mean the honest version of our sentence is now "monohydrate has far more evidence behind it," not "nothing else has been shown to do anything." I have made a note to revisit that article's wording.

How seriously should you take a 36-person study?

Seriously enough to pay attention, not seriously enough to change your routine on its own.

Thirty-six participants split across four arms is roughly nine people per group. That is small. Small trials produce larger-looking effects and wider uncertainty, and they need replication before anyone should treat the numbers as settled.

• Eight weeks is short for cognitive and clinical endpoints, though it is reasonable for detecting a change in brain creatine.
• Reaction time is one narrow slice of cognition. It is not memory, not executive function, not day-to-day clarity.
• A "trend" is not a finding. The mood result did not reach the bar the other outcomes did, and it should be described that way.
• Healthy volunteers may not respond the way someone managing other conditions would.

None of that makes it a bad study. It makes it a first study. That is genuinely how this is supposed to work.

What does this mean if you are in perimenopause or menopause?

It is encouraging directional evidence that supplementation can raise brain creatine and support cognitive measures in exactly the population that has been least studied — and it is not a reason to abandon a 5g monohydrate routine that is already working.

The broader case for this life stage does not rest on this one trial. It rests on the baseline: women carry roughly 70 to 80% lower brain creatine stores than men, and the menopause transition removes estrogen's quiet support of muscle, bone, and brain fuel delivery at the same time. We covered that in creatine and perimenopause and creatine after 50.

This is general education, not medical advice. If you are managing menopause symptoms, taking hormone therapy, or on any medication, talk with your doctor before adding or changing a supplement.

How to read any creatine study without getting fooled

Check five things before you believe a headline: how many people, how long, which form and dose, what was actually measured, and who paid for it.

1. Sample size. Under about 50 participants, treat the effect size as a hypothesis rather than a number.
2. Duration. Muscle saturates in three to four weeks; brain stores appear to fill more slowly. A two-week study cannot see what an eight-week study can.
3. Form and dose. "Creatine improved X" means nothing until you know whether it was 5g of monohydrate or 750mg of something else.
4. The actual endpoint. Reaction time, word recall, and "brain fog" are three different things that headlines routinely blur together.
5. Funding and registration. Pre-registration, like this trial's ClinicalTrials.gov entry, means the outcomes were declared before the data came in.

If a term in a study abstract stops you, most of them are defined in our glossary.

Common questions

Should I switch to creatine HCl because of this study?

No. This trial did not compare HCl against monohydrate, so it cannot tell you one is better. Monohydrate still has vastly more outcome research behind it and is usually cheaper per effective dose.

Does this mean I only need 1,500mg instead of 5g?

Not for monohydrate. The 5g standard comes from the monohydrate literature, and dose recommendations do not transfer between forms. Our reasoning is in the 5g question.

Was the mood improvement real?

It was reported as a trend, which in research language means it moved in a promising direction without meeting the threshold for a confident finding. Worth watching, not worth claiming.

Where can I read the study myself?

It is indexed on PubMed as PMID 40854087 and published in the Journal of the American Nutrition Association. The registration is ClinicalTrials.gov NCT06660004. We would rather you check us than take our word for it.

What we are watching next

Replication of the menopause findings in a larger sample. Any head-to-head of HCl against monohydrate at matched effective doses, which is the study the field actually needs. And longer-horizon work on bone density in postmenopausal women, where creatine's role is still indirect and under-evidenced.

See you next month. If you want the underlying concepts first, Creatine 101 is the place to start, and what all of it adds up to in practice is four Vybrance Labs creatine gummies a day — 5g creatine monohydrate, 120mcg vitamin B12, 500mg taurine.

See you in the wild,

-Lawrence